Search -

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Presentation TCT 2019

Role of New-Gen DES in Patients at HBR: Does Stent Type Matter?

Presenter: Ajay Kirtane

September 28, 2019

Presentation TCT 2019

STOPDAPT-2 HBR: 1-Year Outcomes From a Randomized Trial of Clopidogrel Monotherapy vs. DAPT Beginning 1 Month After PCI in Patients at High Bleeding Risk

Presenter: Hirotoshi Watanabe

September 28, 2019

Presentation TCT 2019

Clinical Trial Design in HBR Patients: Should Risk Scores Be Incoporated?

Presenter: Davide Capodanno

September 27, 2019

Presentation TCT 2019

Idenifying the High Bleeding Risk Patient: The ARC HBR Definitions

Presenter: Philip Urban

September 27, 2019

Presentation TCT 2019

Study Design Considerations for HBR Patients and DES Platforms: FDA View

Presenter: Adrian Magee

September 26, 2019

Presentation TCT 2019

PCI for HBD Patients in Japan: Current Clinical Treatment and Post-Market Treatment

Presenter: Junya Ako

September 26, 2019

Presentation TCT 2019

ARC Definition of High Bleeding Risk: Global Impact on HBR PCI Clinical Studies?

Presenter: Hans-Peter Stoll

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Conference News EuroPCR 2019

New Clarity on Patients at High Risk for Bleeding After PCI

Michael O'Riordan

May 28, 2019

Presentation CIT 2019

The landscape of Ongoing HBR Clinical Trials & an Introduction to HBR-ARC Initiative

Presenter: Roxana Mehran

March 28, 2019

CME

Advertisement

Role of New-Gen DES in Patients at HBR: Does Stent Type Matter?

STOPDAPT-2 HBR: 1-Year Outcomes From a Randomized Trial of Clopidogrel Monotherapy vs. DAPT Beginning 1 Month After PCI in Patients at High Bleeding Risk

Clinical Trial Design in HBR Patients: Should Risk Scores Be Incoporated?

Idenifying the High Bleeding Risk Patient: The ARC HBR Definitions

Study Design Considerations for HBR Patients and DES Platforms: FDA View

PCI for HBD Patients in Japan: Current Clinical Treatment and Post-Market Treatment

ARC Definition of High Bleeding Risk: Global Impact on HBR PCI Clinical Studies?

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

New Clarity on Patients at High Risk for Bleeding After PCI

The landscape of Ongoing HBR Clinical Trials & an Introduction to HBR-ARC Initiative

Updates on Onyx ONE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content